These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37760451)

  • 1. Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer.
    Acton A; Placzek WJ
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.
    Klanova M; Kazantsev D; Pokorna E; Zikmund T; Karolova J; Behounek M; Renesova N; Sovilj D; Kelemen CD; Helman K; Jaksa R; Havranek O; Andera L; Trneny M; Klener P
    Mol Cancer Ther; 2022 Jan; 21(1):89-99. PubMed ID: 34728569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells.
    Duan L; Tadi MJ; O'Hara KM; Maki CG
    J Biol Chem; 2024 Jun; 300(6):107375. PubMed ID: 38762181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 5. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.
    Tseng HY; Dreyer J; Emran AA; Gunatilake D; Pirozyan M; Cullinane C; Dutton-Regester K; Rizos H; Hayward NK; McArthur G; Hersey P; Tiffen J; Gallagher S
    Int J Cancer; 2020 Oct; 147(8):2176-2189. PubMed ID: 32249419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
    Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme.
    Lee A; Jin HO; Masudul Haque M; Kim HY; Jung H; Park JH; Kim I; Song JY; Yoon HK; Kim HK; Han J; Park IC; Kim KS; Park SG
    Int J Oncol; 2022 Jan; 60(1):. PubMed ID: 34913076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X
    Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T
    Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia.
    Seipel K; Schmitter K; Bacher U; Pabst T
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31718075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Kohler S; Bacher U; Pabst T
    Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
    Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
    Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells
    Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O
    Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels.
    De Blasio A; Pratelli G; Drago-Ferrante R; Saliba C; Baldacchino S; Grech G; Tesoriere G; Scerri C; Vento R; Di Fiore R
    J Cell Physiol; 2019 Aug; 234(10):18432-18447. PubMed ID: 30912136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia.
    Seipel K; Kopp B; Bacher U; Pabst T
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
    Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
    Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient.
    Ali SM; Watson J; Wang K; Chung JH; McMahon C; Ross JS; Dicke KA
    Case Rep Oncol; 2016; 9(1):112-8. PubMed ID: 27293397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
    Wong KY; Chim CS
    J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT inhibition sensitizes acute leukemia cells to S63845-induced apoptosis.
    Li Y; Du L; Ye K; Sun X; Hu L; Gao S; Dai H
    Hematology; 2023 Dec; 28(1):2214465. PubMed ID: 37222135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCL1 binds and negatively regulates the transcriptional function of tumor suppressor p73.
    Widden H; Kaczmarczyk A; Subedi A; Whitaker RH; Placzek WJ
    Cell Death Dis; 2020 Nov; 11(11):946. PubMed ID: 33144577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells.
    Lucantoni F; Lindner AU; O'Donovan N; Düssmann H; Prehn JHM
    Cell Death Dis; 2018 Jan; 9(2):42. PubMed ID: 29352235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.